Micromune Therapeutics
PrivateLast Round
Grant
Dec 23, 2024
Total Funding Raised
$2.81M
Company Overview
Micromune Therapeutics is a biotechnology company developing a small molecule therapeutic for inflammatory bowel disease (IBD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Micromune Therapeutics Comparables
Compare Micromune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vedanta Biosciences | 77% | |
| SFA Therapeutics | 77% | |
| Enterome | 76% | |
Micromune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 23, 2024 | ||||
| Grant | May 24, 2023 |
Micromune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CUREator | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 23, 2024
Secured $2.48M in grant funding from CUREator.
Micromune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Micromune Therapeutics's valuation, stock price, and market status.